EGFR and non-small cell lung carcinoma: Subsequently, osimertinib was approved in the first-line setting on the basis of the randomized phase III FLAURA trial, which evaluated the efficacy of upfront osimertinib versus a SoC EGFR TKI (erlotinib or gefitinib) in treatment-naïve EGFR mutant (exon 19 del or L858R) advanced NSCLC patients [47].